
Sign up to save your podcasts
Or


A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By CNBC4.2
526526 ratings
A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

4,100 Listeners

1,366 Listeners

239 Listeners

151 Listeners

518 Listeners

1,173 Listeners

2,175 Listeners

325 Listeners

67 Listeners

153 Listeners

289 Listeners

34 Listeners

45 Listeners

2,145 Listeners

1,320 Listeners

591 Listeners

5 Listeners

21 Listeners

1,573 Listeners

212 Listeners

409 Listeners

300 Listeners

122 Listeners

830 Listeners

175 Listeners

37 Listeners

15 Listeners

33 Listeners

11 Listeners

16 Listeners

0 Listeners